2. Search Result
Search Result
Results for "

Integrin αvβ6

" in MedChemExpress (MCE) Product Catalog:

28

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

7

Peptides

1

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-137561
    Bexotegrast
    3 Publications Verification

    PLN-74809

    		 Integrin Inflammation/Immunology
    Bexotegrast (PLN-74809) is an orally active, potent dual αvβ6/αvβ1 integrin inhibitor with Kd of 5.7 nM and 3.4 nM, respectively. Bexotegrast inhibits αvβ6- and αvβ1-induced TGF-β activation with IC50 values of 29.8 nM and 19.2 nM, respectively. Bexotegrast has antifibrogenic effects and block multiple avenues of TGF-β activation in the fibrotic lung .
    Bexotegrast
  • HY-18644
    CWHM-12
    Maximum Cited Publications
    10 Publications Verification

    		 Integrin Cancer
    CWHM-12 is a potent inhibitor of αV integrins with IC50s of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1.
    CWHM-12
  • HY-15102
    MK-0429
    5+ Cited Publications

    L-000845704

    		 Integrin Inflammation/Immunology Cancer
    MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively .
    MK-0429
  • HY-W087027
    Maleimide-NOTA

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Integrin Cancer
    Maleimide-NOTA is a chelate. Maleimide-NOTA can be site-specifically coupled to the hPD-L1 nanobody bearing the Cys-tag. Maleimide-NOTA can specifically conjugate to A20FMDV2 (HY-P1654). The [ 68Ga]Ac-CG6 formed by the conjugation of 68Ga radiolabeled Maleimide-NOTA with A20FMDV2 can be used for PET imaging of αvβ6 integrin-positive pancreatic ductal adenocarcinoma .
    Maleimide-NOTA
  • HY-19767
    GSK 3008348
    2 Publications Verification

    		 Integrin TGF-β Receptor Infection Inflammation/Immunology Cancer
    GSK 3008348 is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 can be used for research on pulmonary fibrosis and various types of cancer .
    GSK 3008348
  • HY-149136
    MORF-627

    		Integrin TGF-beta/Smad Inflammation/Immunology
    MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .
    MORF-627
  • HY-19767A
    GSK 3008348 hydrochloride
    2 Publications Verification

    		 Integrin TGF-β Receptor Infection Inflammation/Immunology Cancer
    GSK 3008348 hydrochloride is a small molecule antagonist of integrin αvβ6 with IC50 values for αvβ6, αvβ1, αvβ3, αvβ5, and αvβ8 are 1.50, 2.83, 12.53, 4.00, and 2.26 nM, respectively. GSK 3008348 hydrochloride can target the αvβ6 integrin, inhibit TGF-β activation, and thereby alleviate the fibrotic process. GSK 3008348 hydrochloride prevents the binding of the foot-and-mouth disease virus (FMDV) to the αvβ6 integrin receptor on the surface of host cells, thereby inhibiting the entry of the virus. GSK 3008348 hydrochloride can be used for research on pulmonary fibrosis and various types of cancer .
    GSK 3008348 hydrochloride
  • HY-P990667
    STX-100

    		Integrin TGF-beta/Smad Inflammation/Immunology Cancer
    STX-100 is a humanized monoclonal antibody targeting αVβ6 integrin. STX-100 specifically binds αVβ6 integrin, blocks latent TGF-β activation via latency-associated peptide (LAP) interaction prevention, and reduces profibrotic responses. STX-100 can be used for the research of idiopathic pulmonary fibrosis, and cancer .
    STX-100
  • HY-130119
    Integrin-IN-2

    		Integrin Cancer
    Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC50 values of 7.8, 8.4, 8.4 and 7.4, respectively .
    Integrin-IN-2
  • HY-100133A
    DOTA-ADIBO TFA

    		Integrin Cancer
    DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6 .
    DOTA-ADIBO TFA
  • HY-P1654
    A20FMDV2

    		Integrin Cancer
    A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
    A20FMDV2
  • HY-P6351
    c(avb6)-DOTA TFA

    		Integrin Cancer
    c(avb6)-DOTA TFA is a conjugate of the αvβ6 integrin selective peptide ring modified with DOTA chelator. The Lu(III) complex of c(avb6)-DOTA TFA has a comparable affinity for αvβ6 integrin (IC50=0.8 nM) and can be used as a tumor diagnostic .
    c(avb6)-DOTA TFA
  • HY-W008201
    tert-Butyl 3-formylpyrrolidine-1-carboxylate

    		Drug Intermediate Inflammation/Immunology
    tert-Butyl 3-formylpyrrolidine-1-carboxylate is a drug intermediate that can be used for the synthesis nonpeptidic αvβ6 Integrin inhibitors .
    tert-Butyl 3-formylpyrrolidine-1-carboxylate
  • HY-D2062
    ATTO 740 NHS ester

    		Fluorescent Dye Integrin Cancer
    ATTO 740 NHS ester is a near-infrared fluorescent dye and a multimodal fluorescence/photoacoustic contrast agent with excellent near-infrared emission properties and extremely high photostability. The photoacoustic signal of ATTO 740 NHS ester shows no significant decrease after continuous irradiation with a 750 nm laser for 30 min, making it suitable for in vivo fluorescence imaging and photoacoustic contrast imaging. When conjugated with the cystine knot peptide R01, ATTO 740 NHS ester enables precise detection of integrin αvβ6-positive cells and tumors in nude mouse xenograft models .
    ATTO 740 NHS ester
  • HY-153807
    αvβ6 integrin inhibitor 2

    		Integrin Inflammation/Immunology
    αvβ6 integrin inhibitor 2 is a potent ανβ6 integrin inhibitor with an IC50 of 96.5 nM (WO2020081154A1, example 19) .
    αvβ6 integrin inhibitor 2
  • HY-168087
    GSK3335103

    		Integrin Cardiovascular Disease
    GSK3335103 is an orally active, non-peptide αvβ6 integrin inhibitor (pIC50=8). GSK3335103 can be used in the study of pulmonary fibrosis .
    GSK3335103
  • HY-137561A
    Bexotegrast hydrochloride

    PLN-74809 hydrochloride

    		 Integrin Inflammation/Immunology
    Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
    Bexotegrast hydrochloride
  • HY-168522
    αvβ6-IN-2

    		Integrin Inflammation/Immunology
    αvβ6-IN-2 (compound 20) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 7.8. αvβ6-IN-2 has the potential for the research of idiopathic pulmonary fibrosis .
    αvβ6-IN-2
  • HY-168521
    αvβ6-IN-1

    		Integrin Inflammation/Immunology
    αvβ6-IN-1 (compound 28) is a potent and orally active αvβ6 integrin inhibitor with a pIC50 value of 8.1. αvβ6-IN-1 has the potential for the research of idiopathic pulmonary fibrosis .
    αvβ6-IN-1
  • HY-126402
    Arg-Gly-Asp TFA

    		Integrin Cancer
    Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.
    Arg-Gly-Asp TFA
  • HY-P11576
    Cyclic αvβ6

    		Integrin Radionuclide-Drug Conjugates (RDCs) Cancer
    Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with 68Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .
    Cyclic αvβ6
  • HY-185424
    Tri-SM6.1

    		Integrin Others
    Tri-SM6.1 is a tridentate small-molecule ligand targeting integrin αvβ6. Tri-SM6.1 binds to integrin αvβ6 on epithelial cells to deliver conjugated α-ENaC RNAi agents .
    Tri-SM6.1
  • HY-P11596
    NOTA-Asp2-αvβ6L

    		Integrin Cancer
    NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
    NOTA-Asp2-αvβ6L
  • HY-P11708
    Relitegatide

    		Integrin Cancer
    Relitegatide is a cyclic peptide with selectivity for the αvβ6 integrin. Relitegatide can be used for the synthesis of Relitegatide brexetan (HY-P11276) .
    Relitegatide
  • HY-185470
    L123Z358

    		Integrin Others
    L123Z358 is a ligand of αvβ6 integrin. L123Z358 can be conjugated with siRNA to achieve targeted drug delivery to muscle tissue .
    L123Z358
  • HY-179583
    FSC(PEG4-αvβ6)₃

    		Integrin Cancer
    FSC(PEG4-avb6)3 is a tracer targeting αvβ6 integrin trimer (IC50 = 0.69 nM). FSC(PEG4-avb6)3 can be used for the study of head-and-neck, lung, breast, and pancreatic carcinomas .
    FSC(PEG4-αvβ6)₃
  • HY-185425
    SM6.1-azide

    		Integrin Inflammation/Immunology
    SM6.1-azide (Compound 2a) is a ligand for αvβ6 integrin with a azide group. The azide group of SM6.1-azide can undergo a click chemical reaction with small molecules, peptides or siRNA containing DBCO or Alkyne groups, enabling pulmonary-targeted delivery .
    SM6.1-azide
  • HY-P1654A
    A20FMDV2-Cys

    		Integrin Cancer
    A20FMDV2-Cys is a cysteine-containing 20-mer peptide that targets integrin αvβ6 with high affinity. A20FMDV2-Cys can be used for targeted liposome modification to enhance liver and bile duct targeting. A20FMDV2-Cys is applicable for research in drug delivery .
    A20FMDV2-Cys

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: